Workshop 2011 Screening colon retto

Similar documents
Baseline Findings of the Italian Multicenter Randomized Controlled Trial of Once-Only Sigmoidoscopy SCORE

Fecal occult blood testing (FOBT), flexible sigmoidoscopy

Cancer Screening in the European Union Second Report: Colorectal cancer Screening

Haemoglobin level at previous negative FIT and risk of neoplasia at subsequent screening rounds. Carlo SENORE

Performance of Colorectal cancer screening in the European Union Member States Data from the second European screening report

Capsule endoscopy screening. Carlo SENORE

Integrating screening and primary prevention

C olorectal cancer (CRC) is the second most common

Ruolo della biopsia in colposcopia e rischio di carcinoma invasivo. Guglielmo Ronco AOU Città della salute e della scienza di Torino

Nivolumab nel carcinoma renale metastatico: esperienza italiana

EXPERT WORKING GROUP Surveillance after neoplasia removal. Meeting Chicago, May 5th 2017 Chair: Rodrigo Jover Uri Ladabaum

Colorectal cancer screening guidelines clearly recommend. Comparing Risks and Benefits of Colorectal Cancer Screening in Elderly Patients

The choice of methods for Colorectal Cancer Screening; The Dutch experience

Corneal transplantation: HLA and age

THREE MONTHS VERSUS ONE YEAR OF ORAL ANTICOAGULANT THERAPY FOR IDIOPATHIC DEEP VENOUS THROMBOSIS

Person-years; number of study participants (number of cases) HR (95% CI) P for trend

Is aspirin ready for colorectal cancer chemoprevention and adjuvant therapy?

Ripolarizzazione precoce. Non così innocente come si pensava

Disclosure Information Relationships Relevant to this Session

How to improve the reliability of Single Arm Trials

Colorectal Cancer Screening: Colonoscopy, Potential and Pitfalls. Disclosures: None. CRC: still a major public health problem

FORTE: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomas

Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis

Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative

imedpub Journals Quality Assurance of Flexible Sigmoidoscopy as a Screening Tool for Colorectal Cancer Abstract

A/Prof Brian Cox. Cancer Epidemiologist Dunedin

Supplementary Appendix

After primary tumor treatment, 30% of patients with malignant

Screening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee

AUDIT SYSTEM ON QUALITY OF BREAST CANCER DIAGNOSIS AND TREATMENT (QT)

CT Colonography and CRC screening: an update Andrea Laghi M.D.

Prevenzione secondaria dell ischemia cerebrale di origine arteriosa. Marco Cattaneo. Ospedale San Paolo Università degli Studi di Milano

Monitoring the prevalence of diabetes and the quality of care using electronic health data

Prevention of Bowel Cancer: which patients do I send for colonoscopy?

COLON CANCER SCREENING IN CYSTIC FIBROSIS

THE NEW ZEALAND MEDICAL JOURNAL

European Partnership for Screening

Title: Hospitalization rates and cost in severe or complicated obesity: An Italian cohort study.

Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients

Colorectal Cancer Screening and Surveillance

When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool

ESPEN Congress Florence 2008

Measure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care

Compliance with clinical practice guidelines for breast cancer treatment: a population-based study of quality-of-care indicators in Italy

Chapter 3 A literature review of assumptions on test characteristics and adherence in economic evaluations of colonoscopy and CT-colonography

Key Words. Colorectal neoplasms Lung metastases Lung surgery Overall survival

BMC Public Health. Open Access. Abstract

Yield of Advanced Adenoma and Cancer Based on Polyp Size Detected at Screening Flexible Sigmoidoscopy

Citation for published version (APA): Wijkerslooth de Weerdesteyn, T. R. (2013). Population screening for colorectal cancer by colonoscopy

ColonCancerCheck & Regional Updates. Cheryl Shoemaker RN, BScN, CON(C) March 19, 2014

Screening for Colorectal Cancer in the Elderly. The Broad Perspective

Colonoscopy overuse in colorectal cancer screening in Argentina. Ignacio Ricci

Epidemiology and Biostatistics and MTA, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

2 nd EUROPEAN WORKSHOP on CH-EUS and EUS Image Enhancement Techniques

Measure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care

Colorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005

Transplant in MM patients: Early versus late. Mario Boccadoro. Barcelona

Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests

removal of adenomatous polyps detects important effectively as follow-up colonoscopy after both constitute a low-risk Patients with 1 or 2

RESEARCH. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial

Quality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction

Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer

Ripolarizzazione precoce. Non così innocente come si pensava

New Technologies in Surgical Oncology

Tables 1-6 show a summary of main results related on screen detected cases during (age 50-69). Table 7 shows time trends

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma

Relationships of peripheral blood lymphocyte counts (PBLC) with antitumor activity of NGR-hTNF given in combination with chemotherapy (CT)

Colorectal cancer screening

Carcinoma del colon-retto: La Chirurgia Robotica nella Malattia Avanzata

Terapia preventiva del cancro: stato dell arte

SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE

Summary. Cezary ŁozińskiABDF, Witold KyclerABCDEF. Rep Pract Oncol Radiother, 2007; 12(4):

The Dutch bowel cancer screening program Relevant lessions for Ontario

Efficacy, effectiveness, quality: sources of data

Screening di Popolazione. del Cancro Colorettale. C. Hassan

Prof Stephen P. Halloran. Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT

Clin Microbiol Infect Feb;21(2):e11-3. doi: /j.cmi Epub 2014 Oct 29.

La obesidad puede matar: el papel de primaria de la salud y la prevención del cáncer.

NON INVASIVE VENTILATION

Split-dose menthol-enhanced PEG vs PEG-ascorbic acid for colonoscopy preparation

Updates in Colorectal Cancer Screening & Prevention

INTERACTION WITH SCREENEES AND PATIENT ORGANIZATIONS

Follow up The way ahead. John Griffith

Positive Results on Fecal Blood Tests

Preliminary Scientific Program

Research Article Development of Polyps and Cancer in Patients with a Negative Colonoscopy: A Follow-Up Study of More Than 20 Years

Bowel Cancer Screening

Chemo-endocrine prevention of breast cancer

ADENOMA SURVEILLANCE BCSP Guidance Note No 1 Version 1 September 2009

Management of Hematological Cancer in Older People. Ulrich Wedding Riccardo A. Audisio Editors

Provider Contribution to Overuse and Underuse of Colorectal Cancer Screening (mostly colonoscopy)

Colorectal cancer screening: strategies to select populations with moderate risk for disease

under the aegis of cover picture: Chiostro d Onore University of Milan

Risk of invasive cancer after colposcopy with and without biopsy

Liver transplantation: an ongoing challenge

Early Age and Late Stage Diagnosis of Colorectal Cancer Among American Indian Residents of Montana,

Colorectal Adenoma Detection Rate in Northeast Texas Outcome from Community Service Project Using the Fecal Immunochemical Test and Colonoscopy

Chemoprevention of Colorectal Cancer: Where We Stand

Treatment of elderly patients with multiple myeloma

Transcription:

Trial SCORe Workshop 2011 Screening colon retto Nereo Segnan CPO Piemonte e AOU S.Giovanni Battista Torino Torino, 19 ottobre 2011

ONCE-ONLY SIGMOIDOSCOPY SCREENING IN COLORECTAL CANCER SCREENING: FOLLOW UP FINDINGS OF THE ITALIAN RANDOMIZED CONTOLLED TRIAL SCORE JNCI 2011 Sep 7;103(17):1310-22. Epub 2011 Aug 18. Nereo Segnan, Paola Armaroli, Luigina Bonelli, Mauro Risio, Stefania Sciallero, Marco Zappa, Bruno Andreoni, Arrigo Arrigoni, Luigi Bisanti, Claudia Casella, Cristiano Crosta, Fabio Falcini, Franco Ferrero, Adriano Giacomin, Orietta Giuliani, Alessandra Santarelli, Carmen Beatriz Visioli, Roberto Zanetti, Wendy S Atkin, Carlo Senore; SCORE working group collaborators

SCORE Trial profile-2 34292 RANDOMIZED 17148 INTERVENTION 17144 CONTROL 4 deaths 8 CRCs diagnoses occurring before randomization 17136 Followed-up 17136 Followed-up 1 death 7 CRCs diagnoses occurring before randomization 7138 (42%) Do not attend 9911 (58%) examined 87 attend: FS not performed 1 patient who refused to repeat the FS following inadequate preparation, had been diagnosed with a CRC prior to randomization. He was therefore excluded from the follow-up analysis.

FOLLOW-UP Participants were followed-up until 31/12/2007 for incidence 31/12/2008 for mortality Median follow-up time to death, emigration, or end of follow-up: 10.5 years (IQR=9.9-11.3) for incidence 11.4 years (IQR=10.8-11.9) for mortality

Intention to treat analysis - Colorectal cancer INCIDENCE, ALL SITES Nelson Aalen Cumulative Hazard (%) by time from randomization 2.00 1.50 1.00 0.50 RR (95%CI) = 0.82 (0.69-0.96) 1 2 3 4 5 6 7 8 9 10 11 Time from randomization-years Control Intervention Cumulative Events by years from randomization 2 4 6 8 Control 60 104 165 223 Intervention 75 111 152 195 10 286 237 >10 306 251

Intention to treat analysis-colorectal cancer INCIDENCE, Distal&Descendent Nelson Aalen Cumulative Hazard (%) by time from randomization 1.20 0.90 0.60 0.30 RR (95%CI) = 0.76 (0.62-0.94) 1 2 3 4 5 6 7 8 9 10 11 Time from randomization-years Control Intervention Cumulative Events by years from randomization 2 4 6 8 Control 37 67 110 151 Intervention 58 80 104 126 10 187 143 >10 198 152

Intention to treat analysis-colorectal cancer MORTALITY, ALL SITES Nelson Aalen Cumulative Hazard (%) by time from randomization 0.50 0.37 0.25 0.12 RR (95%CI) = 0.78 (0.56-1.08) 1 2 3 4 5 6 7 8 9 10 11 Time from randomization-years Control Intervention Cumulative Events by years from randomization 2 4 6 8 Control 6 17 34 47 Intervention 4 17 28 41 10 62 52 >10 83 65

Per protocol analysis-colorectal cancer INCIDENCE, ALL SITES Nelson Aalen Cumulative Hazard (%) by time from randomization 2.00 1.50 1.00 0.50 RR (95%CI) = 0.69 (0.56-0.86) 1 2 3 4 5 6 7 8 9 10 11 Time from randomization-years Control Screened Not screened Cumulative Events by years from randomization 2 4 6 8 Control 60 104 165 223 Not Screened 18 41 68 94 Screened 57 70 84 101 10 286 116 121 >10 306 125 126

Per protocol analysis-colorectal cancer INCIDENCE, Distal&Descendent Nelson Aalen Cumulative Hazard (%) by time from randomization 1.20 0.90 0.60 0.30 RR (95%CI) = 0.60 (0.46-0.80) 1 2 3 4 5 6 7 8 9 10 11 Time from randomization-years Control Screened Not screened Cumulative Events by years from randomization 2 4 6 8 Control 37 67 110 151 Not Screened 11 28 48 65 Screened 47 52 56 61 10 187 75 68 >10 198 81 71

Per protocol analysis-colorectal cancer MORTALITY, ALL SITES Nelson Aalen Cumulative Hazard (%) by time from randomization 0.50 0.37 0.25 0.12 RR (95%CI) = 0.62 (0.40-0.96) 1 2 3 4 5 6 7 8 9 10 11 Time from randomization-years Control Screened Not screened Cumulative Events by years from randomization 2 4 6 8 Control 6 17 34 47 Not Screened 1 8 14 19 Screened 3 9 14 22 10 62 25 27 >10 83 35 30

Contributing members of the SCORE Working Group: Arezzo: A. Carnevali (Pathology Unit, San Donato Hospital, AUSL 8 Arezzo), A. Agnolucci and P. Ceccatelli (Endoscopy Unit, San Donato Hospital, AUSL 8 Arezzo), F. Mirri (Screening Unit, Valdarno Hospital); Biella: A. Azzoni (Gastroenterology Unit, Infermi Hospital, ASL Biella), M. Giudici (Pathology Unit, Infermi Hospital, ASL Biella), G. Genta and A. Marutti (E Tempia Foundation); Genoa: A. Guelfi Screening Unit, National Cancer Institute, Genoa), B. Gatteschi Unit of Pathology, National Cancer Institute, Genova; Milan: C. Zocchetti (Regional Health Authority- Regione Lombardia), M. Autelitano Epidemiology Unit, ASL Città di Milano), G. Fiori (Endoscopy Unit, European Institutre of Oncology); Rimini: G. Fabbretti (Pathology Unit, Infermi Hospital, AUSL Rimini), S. Gasperoni (Gastroenterology Unit, S Maria delle Croci Hospital, Ravenna); Turin: M. Fracchia, R.Rocca (Gastoenterology Unit Ospedale Mmauriziano Umberto I),A. Bertone, M. Pennazio, M. Spandre (Gastroenterology Unit, San Giovanni AS Hospital, AOU S Giovanni Battista), S. Patriarca, and S. Rosso (Piedmont Cancer Registry and CPO Piemonte), D. Brunetti (CPO Piemonte), M. Demaria (ARPA Piemonte)

Atkin WS et al. Lancet 2010;375:1624-33 N. Segnan CPO 2010

Colorectal cancer incidence (Kaplan-Meier estimates) HR=0,77 HR=0.67 intention-to-treat analysis per-protocol analysis N. Segnan CPO 2010

Distal cancer incidence (Kaplan-Meier estimates) HR=0.64 HR=0.50 intention-to-treat analysis per-protocol analysis N. Segnan CPO 2010

Colorectal cancer mortality (Kaplan-Meier estimates) HR=0.69 HR=0.57 intention-to-treat analysis per-protocol analysis N. Segnan CPO 2010

European guidelines on colorectal cancer screening Level of evidence FOBT I Sigmoidoscopy II Colonoscopy III